Systemic Lupus Erythematosus Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook

Systemic Lupus Erythematosus Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Systemic Lupus Erythematosus pipeline constitutes 55+ key companies continuously working towards developing 60+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 The Systemic Lupus Erythematosus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Systemic Lupus Erythematosus Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Systemic Lupus Erythematosus Market.

 

Some of the key takeaways from the Systemic Lupus Erythematosus Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Systemic Lupus Erythematosus treatment therapies with a considerable amount of success over the years. 
  • Systemic Lupus Erythematosus companies working in the treatment market are I-Mab Biopharma, Roche, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others, are developing therapies for the Systemic Lupus Erythematosus treatment 
  • Emerging Systemic Lupus Erythematosus therapies such as – TJ202, Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others are expected to have a significant impact on the Systemic Lupus Erythematosus market in the coming years.   
  • On February 1, 2022, Biogen Inc. announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies’ long-standing collaboration on antibodies targeting CD20. Mosunetuzumab is currently in Phase Ib stage of development in people with SLE.
  • A Phase II b study of rozibafusp alfa, a multispecific antibody-peptide fusion that simultaneously blocks inducible T-cell costimulatory ligand (ICOSL) and B-cell activating factor (BAFF) activity, is being investigated to treat patients with Systemic Lupus Erythematosus
  • In June 2021, Viela Bio (Subsidiary of Horizon Therapeutics) initiated a Phase II randomized, double-blind, placebo-controlled efficacy and safety study of VIB7734 for the treatment of moderate to severely active Systemic Lupus Erythematosus in approximately 195 participants
  • In July 2021, Biogen initiated a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus receiving background non biologic lupus standard of care

 

Systemic Lupus Erythematosus Overview

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms.

 

Get a Free Sample PDF Report to know more about Systemic Lupus Erythematosus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-pipeline-insight

 

Emerging Systemic Lupus Erythematosus Drugs Under Different Phases of Clinical Development Include:

  • TJ202: I-Mab Biopharma
  • Mosunetuzumab: Roche
  • Itolizumab: Equillium/ Biocon Limited
  • KPG 818: Kangpu Biopharmaceuticals
  • BOS161721: Boston Pharmaceuticals
  • NKTR-358: Nektar Therapeutics
  • ABBV-599: AbbVie
  • Obinutuzumab (Gazyva): Roche
  • Dapirolizumab pegol: UCB
  • PRV 3279: Provention Bio
  • Daxdilimab (VIB7734): Horizon Therapeutics
  • SAR441344: Sanofi
  • BIIB059: Biogen
  • Obinutuzumab: Hoffman-La-Roche

 

Route of Administration

Systemic Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule 

 

Systemic Lupus Erythematosus Pipeline Therapeutics Assessment

  • Systemic Lupus Erythematosus Assessment by Product Type
  • Systemic Lupus Erythematosus By Stage and Product Type
  • Systemic Lupus Erythematosus Assessment by Route of Administration
  • Systemic Lupus Erythematosus By Stage and Route of Administration
  • Systemic Lupus Erythematosus Assessment by Molecule Type
  • Systemic Lupus Erythematosus by Stage and Molecule Type

 

DelveInsight’s Systemic Lupus Erythematosus Report covers around 60+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Systemic Lupus Erythematosus product details are provided in the report. Download the Systemic Lupus Erythematosus pipeline report to learn more about the emerging Systemic Lupus Erythematosus therapies

 

Some of the key companies in the Systemic Lupus Erythematosus Therapeutics Market include:

Key companies developing therapies for Systemic Lupus Erythematosus are – AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

 

Systemic Lupus Erythematosus Pipeline Analysis:

The Systemic Lupus Erythematosus pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Lupus Erythematosus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Lupus Erythematosus Treatment.
  • Systemic Lupus Erythematosus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Systemic Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Lupus Erythematosus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Systemic Lupus Erythematosus drugs and therapies

 

Systemic Lupus Erythematosus Pipeline Market Drivers

  • Promising Therapeutic Approaches, increasing Awareness of the Disease, recent Advancements in Research and Development are some of the important factors that are fueling the Systemic Lupus Erythematosus Market.

 

Systemic Lupus Erythematosus Pipeline Market Barriers

  • However, obstacles in Systemic Lupus Erythematosus Pipeline, hit and Trial Approach of Researchers, high Annual Cost of therapies and other factors are creating obstacles in the Systemic Lupus Erythematosus Market growth.

 

Scope of Systemic Lupus Erythematosus Pipeline Drug Insight    

  • Coverage: Global
  • Key Systemic Lupus Erythematosus Companies: I-Mab Biopharma, Roche, Equillium, Biocon Limited, Kangpu Biopharmaceuticals, Boston Pharmaceuticals, Nektar Therapeutics, AbbVie, Horizon Therapeutics, Sanofi, Biogen, Hoffman-La-Roche, and others
  • Key Systemic Lupus Erythematosus Therapies: TJ202, Mosunetuzumab, Itolizumab, KPG 818, BOS161721, NKTR-358, ABBV-599, Daxdilimab (VIB7734), SAR441344, BIIB059, Obinutuzumab, and others
  • Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
  • Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers 

 

Request for Sample PDF Report for Systemic Lupus Erythematosus Pipeline Assessment and clinical trials

 

Table of Contents

1

Systemic Lupus Erythematosus Report Introduction

2

Systemic Lupus Erythematosus Executive Summary

3

Systemic Lupus Erythematosus Overview

4

Systemic Lupus Erythematosus- Analytical Perspective In-depth Commercial Assessment

5

Systemic Lupus Erythematosus Pipeline Therapeutics

6

Systemic Lupus Erythematosus Late Stage Products (Phase II/III)

7

Systemic Lupus Erythematosus Mid Stage Products (Phase II)

8

Systemic Lupus Erythematosus Early Stage Products (Phase I)

9

Systemic Lupus Erythematosus Preclinical Stage Products

10

Systemic Lupus Erythematosus Therapeutics Assessment

11

Systemic Lupus Erythematosus Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Systemic Lupus Erythematosus Key Companies

14

Systemic Lupus Erythematosus Key Products

15

Systemic Lupus Erythematosus Unmet Needs

16 

Systemic Lupus Erythematosus Market Drivers and Barriers

17

Systemic Lupus Erythematosus Future Perspectives and Conclusion

18

Systemic Lupus Erythematosus Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services


Posted

in

by

Tags: